Clinical trials for malignant melanoma and angiosarcoma using the CICS thermal neutron generator
A theme involving joint clinical trials for malignant melanoma and angiosarcoma using the thermal neutron generator developed by CICS. A 50.0% response rate was confirmed in the Phase II angiosarcoma trial, leading to a partial-change application.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.